Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
Quick Facts
What This Study Found
Patients with PAD had a ~35% increased risk of major cardiovascular events, but both liraglutide and semaglutide showed beneficial effects.
Key Numbers
How They Did This
The study analyzed data from the LEADER and SUSTAIN 6 trials, comparing liraglutide and semaglutide to placebo in patients with type 2 diabetes and high cardiovascular risk.
Why This Research Matters
Understanding the cardiovascular benefits of these medications can help improve treatment strategies for diabetic patients at high risk of heart disease.
What This Study Doesn't Tell Us
The study's findings are based on trial data, which may not fully represent real-world scenarios.
Trust & Context
- Original Title:
- Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
- Published In:
- Diabetes, obesity & metabolism, 24(7), 1288-1299 (2022)
- Authors:
- Verma, Subodh(15), Al-Omran, Mohammed, Leiter, Lawrence A(4), Mazer, C David, Rasmussen, Søren, Saevereid, Hans A, Sejersten Ripa, Maria, Bonaca, Marc P
- Database ID:
- RPEP-06564
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06564APA
Verma, Subodh; Al-Omran, Mohammed; Leiter, Lawrence A; Mazer, C David; Rasmussen, Søren; Saevereid, Hans A; Sejersten Ripa, Maria; Bonaca, Marc P. (2022). Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.. Diabetes, obesity & metabolism, 24(7), 1288-1299. https://doi.org/10.1111/dom.14700
MLA
Verma, Subodh, et al. "Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.." Diabetes, 2022. https://doi.org/10.1111/dom.14700
RethinkPeptides
RethinkPeptides Research Database. "Cardiovascular efficacy of liraglutide and semaglutide in in..." RPEP-06564. Retrieved from https://rethinkpeptides.com/research/verma-2022-cardiovascular-efficacy-of-liraglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.